












### COVID-19 Vaccines Approved for Use in Canada: mRNA vaccines

COVID-19 Formulations	Moderna (Spikevax™)	Moderna (Spikevax™)	Moderna (Spikevax™)	Moderna (Spikevax™) Bivalent BA 4/5	Pfizer (Comirnaty™)	Pfizer (Comirnaty™)	Pfizer (Comirnaty™) Bivalent BA 4/5	Pfizer (Comirnaty™)	Pfizer (Comirnaty™) Bivalent BA 4/5
Vaccine Type	mRNA	mRNA	mRNA	mRNA bivalent	mRNA	mRNA	mRNA bivalent	mRNA	mRNA bivalent
Cap and Label Colour	 Royal Blue cap/ Purple label	 Red cap/ Light blue label	 Red cap/Light blue label	 Royal Blue cap/ grey label (+Bivalent)	 Maroon cap and label	 Orange cap and label	 Orange cap and label (+Bivalent)	 Grey cap and label	 Grey cap and label (+Bivalent)
Formats available	Multidose (0.10 mg/ml) 10 doses/vial	Multidose (0.20 mg/ml) 20 doses/vial	Multidose (0.20 mg/ml) 10 doses/vial	Multidose (0.10 mg/ml) 5 doses/vial	Multidose 10 doses/vial	Multidose 10 doses/vial	Multidose 10 doses/vial	Multidose 6 doses/vial	Multidose 6 doses/vial
Authorized Age Group	6 months to less than 5 years	6 to less than 12 years	12 years and older	18 years and older	6 months to less than 5 years	5 to less than 12 years	5 to less than 12 years	12 years and older	12 years and older
Dose and Injection Volume	0.25ml 25 mcg	0.25ml 50 mcg	0.5ml 100 mcg	0.5ml 50 mcg	0.2ml 3 mcg	0.2ml 10 mcg	0.2ml 10 mcg	0.3ml 30 mcg	0.3ml 30 mcg
Dilution	None	None	None	None	2.2ml/vial	1.3ml/vial	1.3ml/vial	None	None
Routine schedule (primary series)	2 Doses Interval: 8 weeks	2 Doses Interval: 8 weeks	2 Doses Interval: 8 weeks	Not for use in primary series	3 doses Interval: 8 weeks between each dose	2 Doses Interval: 8 weeks	Not for use in primary series	2 Doses Interval: 8 weeks	Not for use in primary series
Booster Dose	N/A	N/A	50 mcg * 6 months **	6 months **	N/A	6 months**	6 months**	6 months**	6 months**
Date Authorized (primary dose)	July 14/22	Mar 17/22	Aug 27/21	N/A	Sept 9/22	Nov 19/21	N/A	March 16/22	N/A
Date Authorized (booster dose)	N/A	N/A	Nov 12/21	Sept 1/22	N/A	Aug 19/22	Dec 9/22	March 16/22	Oct 7/22
Product Monograph	For links to the Covid-19 vaccine product monographs and resources refer to: <a href="https://www.gov.mb.ca/health/immunization/covid-19/">Province of Manitoba   Information for Health Care Professionals (gov.mb.ca)</a>								

\*Individuals who are immunocompromised; living in a PCH/EPH; 70 years and older; or who received 2 non-Health Canada approved vaccines are recommended to have a first booster dose of 100mcg.

\*\*Recommended interval for optimum immune response is 6 months after primary series or previous booster dose as vaccine effectiveness increases with a longer duration between doses.

COVID-19 Vaccines Approved for Use in Canada: non-mRNA vaccines		
COVID-19 Formulations	Novavax (Nuvaxovid™)	Janssen (Jcovden™)
Vaccine Type	Protein Subunit	Viral Vector
Cap Colour		
	<b>Blue Cap</b>	<b>Blue Cap</b>
Formats Available	Multidose 10 doses/vial	Multidose 5 doses/vial
Authorized Age Group	12 years and older	18 years and older
Dose and Injection Volume	0.5ml 5 mcg	0.5ml 5 × 10 <sup>10</sup> virus particles/0.5 mL
Dilution	None	None
Routine schedule (primary series)	2 Doses given 8 weeks apart	1 dose
Booster Dose	<b>18 years and older:</b> 0.5 ml (5 mcg) 6 months (see ** note on previous page )	18 years and older: 0.5 mL 6 months (see ** note on previous page )
Date Authorized (primary dose)	Feb 17/22	Mar 5/21
Date Authorized (booster dose)	Nov. 17/22	May 12/22
Product Monograph	<a href="https://www.gov.mb.ca/health/healthcare/professionals/information-for-health-care-professionals">Province of Manitoba   Information for Health Care Professionals (gov.mb.ca)</a>	

Influenza and Pneumococcal Vaccines Approved for Use in Canada: 2022-2023					
Formulations	<b>Fluzone® Quadrivalent</b>	<b>FluLaval® Tetra</b>	<b>Alfurria® Tetra</b>	<b>Fluzone® High Dose</b>	<b>Pneumovax®23 (Pneu-P-23)</b>
Vaccine Type	IIV4-SD	IIV4-SD	IIV4-SD	IIV4-HD	Pneumococcal polysaccharide 23-valent
Formats Available	0.5 mL single dose prefilled syringe <i>or</i> 5.0 mL multidose vial (10 doses/vial)	5.0 mL multidose vial (10 doses/vial)	0.5 mL single dose prefilled syringe <i>or</i> 5.0 mL multidose vial (10 doses/vial)	0.7 ml Single dose prefilled syringe	0.5 ml single dose prefilled syringe <i>or</i> 0.5 ml single dose vial
Authorized Age Group	6 months and older	6 months and older	<u>5 years and older</u>	65 years and older	65 years and older
Injection Volume	0.5ml	0.5ml	0.5ml	0.7ml	0.5ml
Dose Schedule	<b>*1 or 2 doses:</b> children 6 months to less than 9 years  <b>1 dose:</b> ≥ 9 years	<b>*1 or 2 doses:</b> children 6 months to less than 9 years  <b>1 dose:</b> ≥ 9 years	<b>**1 or 2 doses:</b> children <u>5 years</u> to less than 9 years  <b>1 dose:</b> ≥ 9 years	1 dose	1 dose
Product Monograph	<a href="#">Fluzone PM</a>	<a href="#">FluLaval PM</a>	<a href="#">Afluria PM</a>	<a href="#">High Dose PM</a>	<a href="#">Pnuemo PM</a>

\* Children 6 months to less than 9 years of age who have NOT previously been vaccinated against influenza should receive a second dose of 0.5 mL after an interval of at least 4 weeks.

\*\*Children 5 years to less than 9 years of age who have NOT previously been vaccinated against influenza should receive a second dose of 0.5 mL after an interval of at least 4 weeks.